[go: up one dir, main page]

MX2022014468A - Tratamiento para la amiloidosis. - Google Patents

Tratamiento para la amiloidosis.

Info

Publication number
MX2022014468A
MX2022014468A MX2022014468A MX2022014468A MX2022014468A MX 2022014468 A MX2022014468 A MX 2022014468A MX 2022014468 A MX2022014468 A MX 2022014468A MX 2022014468 A MX2022014468 A MX 2022014468A MX 2022014468 A MX2022014468 A MX 2022014468A
Authority
MX
Mexico
Prior art keywords
amyloidosis
treatment
compounds
formula
amyloid
Prior art date
Application number
MX2022014468A
Other languages
English (en)
Inventor
Peter Qinhua Huang
Kevin Duane Bunker
Joseph Robert Pinchman
Ahmed Abdi Samatar
Original Assignee
Recurium Ip Holdings Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Recurium Ip Holdings Llc filed Critical Recurium Ip Holdings Llc
Publication of MX2022014468A publication Critical patent/MX2022014468A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • External Artificial Organs (AREA)

Abstract

En la presente descripción se describen compuestos de la Fórmula (A) como se definen en la presente descripción, y combinaciones de compuestos, para tratar la amiloidosis. Algunos de los tipos de amiloidosis que se tratan incluyen amiloidosis de cadena ligera amiloide (AL), amiloidosis amiloide tipo A (AA), amiloidosis relacionada con la diálisis (ARD), amiloidosis familiar o hereditaria, amiloidosis sistémica relacionada con la edad (senil) y amiloidosis específica de órgano. En diversas modalidades, un compuesto de la Fórmula (A) se usa en combinación con un corticosteroide para el tratamiento de la amiloidosis.
MX2022014468A 2020-05-19 2021-05-17 Tratamiento para la amiloidosis. MX2022014468A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063027194P 2020-05-19 2020-05-19
PCT/US2021/032808 WO2021236543A1 (en) 2020-05-19 2021-05-17 Treatment for amyloidosis

Publications (1)

Publication Number Publication Date
MX2022014468A true MX2022014468A (es) 2023-02-09

Family

ID=78708017

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022014468A MX2022014468A (es) 2020-05-19 2021-05-17 Tratamiento para la amiloidosis.

Country Status (12)

Country Link
US (1) US20230210846A1 (es)
EP (1) EP4138837A4 (es)
JP (1) JP2023527741A (es)
KR (1) KR20230013102A (es)
CN (1) CN116133661A (es)
AU (1) AU2021273731A1 (es)
BR (1) BR112022023486A2 (es)
CA (1) CA3183746A1 (es)
IL (1) IL298297A (es)
MX (1) MX2022014468A (es)
TW (1) TW202207931A (es)
WO (1) WO2021236543A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023114877A1 (en) * 2021-12-15 2023-06-22 Recurium Ip Holdings, Llc Triple therapy combinations of bcl-2 inhibitors, wee-1 inhibitors and other chemotherapeutic agents

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250008139A (ko) * 2018-01-10 2025-01-14 리커리엄 아이피 홀딩스, 엘엘씨 벤즈아미드 화합물
WO2019199899A1 (en) * 2018-04-09 2019-10-17 Case Western Reserve University Bioink and crosslinkable support medium for printing
ES2940785T3 (es) * 2018-04-10 2023-05-11 Ddp Specialty Electronic Materials Us Llc Dispensador para lata con carcasa fija de vástago de válvula
US10523864B2 (en) * 2018-04-10 2019-12-31 Facebook, Inc. Automated cinematic decisions based on descriptive models

Also Published As

Publication number Publication date
KR20230013102A (ko) 2023-01-26
AU2021273731A1 (en) 2022-12-15
US20230210846A1 (en) 2023-07-06
TW202207931A (zh) 2022-03-01
IL298297A (en) 2023-01-01
CA3183746A1 (en) 2021-11-25
CN116133661A (zh) 2023-05-16
BR112022023486A2 (pt) 2023-01-10
WO2021236543A1 (en) 2021-11-25
EP4138837A4 (en) 2024-05-22
EP4138837A1 (en) 2023-03-01
JP2023527741A (ja) 2023-06-30

Similar Documents

Publication Publication Date Title
CO2021015624A2 (es) Compuestos de 1-oxo-isoindolin-5-carboxamida sustituída, composiciones de estos y métodos de tratamiento con dichos compuestos
EA202092248A1 (ru) Замещенные соединения 4-аминоизоиндолин-1,3-диона, их композиции и способы лечения ими
ATE548354T1 (de) Ureido-substituierte benzoesäureverbindungen und ihre verwendung für die nonsense-suppression und behandlung von erkrankungen
MX2020011495A (es) Inhibidores de bcl-2.
MX2022014468A (es) Tratamiento para la amiloidosis.
WO2019169065A3 (en) Wee1 kinase inhibitors and methods of treating cancer using the same
UA92355C2 (en) urn:schemas-microsoft-com:office:smarttags2,4-DIAMINO-PYRIMIDINES USED AS AURORAINHIBITORS
NO20080942L (no) Amino-5-[4-(difluormetoksy)-fenyl]-5-fenylimidazolonforbindelser som inhibitorer av beta-sekretase (BACE)
SA521430751B1 (ar) Kcnt1 مثبطات وطرق استخدامها
MX2021014531A (es) Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos.
BRPI0606690A2 (pt) composto; uso do composto para o tratamento de uma doença ou distúrbio associado com uma atividade excessiva de bace; e composição farmacêutica
CY1124762T1 (el) Αναστολεις πρωτεïνης δεσμευσης creb (cbp)
CR20240296A (es) Inhibidores parp1
MX2019011506A (es) Inhibicion de cinasa 1 de punto de control (chk1) para el tratamiento de cancer.
MX2009005649A (es) Tratamiento para mieloma multiple.
NO20045214L (no) Cyklotiokarbamatderivater som BR modulatorere og anvendelse derav for behandling av hudlidelser
EA202192122A1 (ru) Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения
SA522441857B1 (ar) مركبات ربط سيريبلون، توليفات منها، وطرق للمعالجة باستخدامها
WO2021089768A3 (en) Treatment and prevention of a neurodegenerative disorder
NZ759585A (en) Agent for preventing or treating brain atrophy
TW200509948A (en) Prevention of urogenital infections
EA202091684A1 (ru) Новый галактозидный ингибитор галектинов
WO2007149875A3 (en) Compositions and methods for treating, preventing and/or reversing type-1 diabetes
ZA202105742B (en) Modulators of malat1 expression
TR200201724T2 (tr) Antihipertansiyon ve buna bağlı belirtileri tedavi etmek için method ve formüller